To the Editor: Prostate-specific antigen (PSA) testing and prostate cancer, the focus of a number of recent articles in the Journal and a widely debated topic, are also the subject of an imminent position paper by the National Health and Medical Research Council (NHMRC). Given that there is general agreement on the potential for overdiagnosis and overtreatment of prostate cancer, it is important to continue our efforts to identify high-risk patients and patients for whom treatment is beneficial. The tools we have for this are the digital rectal examination, the PSA test and its refinements, and biopsy with Gleason scoring and its refinements.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.